Medical Data Vision Future Growth
Future criteria checks 4/6
Medical Data Vision is forecast to grow earnings and revenue by 40.6% and 12.1% per annum respectively. EPS is expected to grow by 40.6% per annum. Return on equity is forecast to be 20% in 3 years.
Key information
40.6%
Earnings growth rate
40.6%
EPS growth rate
Healthcare Services earnings growth | 16.9% |
Revenue growth rate | 12.1% |
Future return on equity | 20.0% |
Analyst coverage | Low |
Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
Medical Data Vision (TSE:3902) Is Due To Pay A Dividend Of ¥6.50
Dec 20Medical Data Vision (TSE:3902) Will Pay A Dividend Of ¥6.50
Nov 15Medical Data Vision (TSE:3902) Will Pay A Dividend Of ¥6.50
Oct 03Medical Data Vision (TSE:3902) Has Affirmed Its Dividend Of ¥6.50
Sep 19Medical Data Vision (TSE:3902) Has Affirmed Its Dividend Of ¥6.50
Aug 10Medical Data Vision Co., Ltd. (TSE:3902) Stocks Shoot Up 25% But Its P/E Still Looks Reasonable
Jun 25Why Medical Data Vision Co., Ltd. (TSE:3902) Could Be Worth Watching
Jun 13Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 9,043 | 1,100 | 866 | N/A | 3 |
12/31/2025 | 8,027 | 853 | 681 | N/A | 3 |
12/31/2024 | 6,500 | 175 | 200 | N/A | 2 |
9/30/2024 | 6,057 | 6 | N/A | N/A | N/A |
6/30/2024 | 6,197 | 448 | 103 | 250 | N/A |
3/31/2024 | 6,248 | 689 | N/A | N/A | N/A |
12/31/2023 | 6,419 | 979 | 1,586 | 1,616 | N/A |
9/30/2023 | 6,264 | 753 | N/A | N/A | N/A |
6/30/2023 | 6,250 | 793 | 1,517 | 1,577 | N/A |
3/31/2023 | 6,152 | 832 | N/A | N/A | N/A |
12/31/2022 | 6,104 | 870 | 857 | 910 | N/A |
9/30/2022 | 6,047 | 1,164 | N/A | N/A | N/A |
6/30/2022 | 5,893 | 1,125 | 967 | 989 | N/A |
3/31/2022 | 5,754 | 1,091 | N/A | N/A | N/A |
12/31/2021 | 5,672 | 1,087 | 1,058 | 1,082 | N/A |
9/30/2021 | 5,378 | 872 | N/A | N/A | N/A |
6/30/2021 | 5,168 | 865 | 1,223 | 1,253 | N/A |
3/31/2021 | 4,966 | 858 | N/A | N/A | N/A |
12/31/2020 | 4,579 | 700 | 937 | 964 | N/A |
9/30/2020 | 4,422 | 770 | N/A | N/A | N/A |
6/30/2020 | 4,286 | 700 | 722 | 738 | N/A |
3/31/2020 | 4,199 | 637 | N/A | N/A | N/A |
12/31/2019 | 4,026 | 554 | 1,121 | 1,202 | N/A |
9/30/2019 | 3,931 | 522 | N/A | N/A | N/A |
6/30/2019 | 3,891 | 329 | 490 | 607 | N/A |
3/31/2019 | 3,743 | 188 | N/A | N/A | N/A |
12/31/2018 | 3,577 | 69 | 2 | 120 | N/A |
9/30/2018 | 3,519 | 137 | N/A | N/A | N/A |
6/30/2018 | 3,364 | 182 | N/A | 231 | N/A |
3/31/2018 | 3,283 | 257 | N/A | N/A | N/A |
12/31/2017 | 3,225 | 354 | N/A | 486 | N/A |
9/30/2017 | 3,009 | 178 | N/A | N/A | N/A |
6/30/2017 | 2,929 | 272 | N/A | 635 | N/A |
12/31/2016 | 2,632 | 178 | N/A | 196 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3902's forecast earnings growth (40.6% per year) is above the savings rate (0.3%).
Earnings vs Market: 3902's earnings (40.6% per year) are forecast to grow faster than the JP market (7.9% per year).
High Growth Earnings: 3902's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 3902's revenue (12.1% per year) is forecast to grow faster than the JP market (4.2% per year).
High Growth Revenue: 3902's revenue (12.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3902's Return on Equity is forecast to be low in 3 years time (20%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/21 04:51 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medical Data Vision Co., Ltd. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Yushi Kawamoto | Haitong International Research Limited |
Masatoshi Nagata | Ichiyoshi Research Institute Inc. |
Hangil Moon | Jefferies LLC |